Introduction {#sec1-1}
============

Evaluating a suspected bleeding disorder is one of the most challenging presentations in hematology. Severe deficiency of vitamin K-dependent proteins in patients not on vitamin K antagonists is often associated with poisoning or surreptitious ingestion of warfarin or potent rodenticides, such as brodifacoum.\[[@ref1]\] Vitamin K antagonists such as warfarin inhibit vitamin K epoxide reductase (VKOR) to disrupt the vitamin K cycle, lowering the functional levels of vitamin K-dependent blood coagulation proteins such as factors II, VII, IX, and X, as well as proteins C and S.\[[@ref2][@ref3]\] Patients are at high risk for complications such as bruising, ecchymoses, purpura and bleeding.\[[@ref3]\] In psychogenic purpura (Gardner-Diamond syndrome), warfarin is ingested surreptitiously as a manifestation of an underlying psychiatric disorder.\[[@ref4]\] Our case highlights a unique presentation of vitamin K antagonist overdose associated with Munchausen syndrome.

Clinical Case {#sec1-2}
=============

A woman with history of hypertension, depression, infiltrating ductal carcinoma of the right breast treated with lumpectomy (T2 N0 disease), post-operative cycles of cyclophosphamide and taxotere and adjuvant radiation therapy, currently on letrozole. She presented with 2-day history of ecchymoses, gingival bruising and hematuria. Medications include letrozole, spironolactone, sertraline and carvedilol. She works as a medical coordinator at a healthcare facility. She denies any ingestion of potent rodenticides. She denies rodenticide aerosols at her workplace, any paint or construction work around her home. Clinical examination revealed a well-nourished woman with extensive ecchymoses on both hands, forearms, elbows, abdomen, back, flank areas and low back pain.

Our initial laboratory evaluation of the patient is reported in [Table 1](#T1){ref-type="table"}. The coagulation panel demonstrated prolonged PT and PTT. Initial INR was \>12.0. The initial blood count showed no schistocytes. Fibrinogen 469 mg/dL, age-adjusted quantitative D-dimer 0.35 mg/L and fibrin degradation products were \<10 ug/dL. Inhibitor factor assays and factor levels were sent at admission. She received 2 doses of intravenous (IV) Vitamin K 10 mg and repeat INR was 4.2. INR levels normalized and she was discharged home with prompt follow-up with her primary care physician (PCP).

###### 

Initial laboratory test results of patient

  Factor tested                        Test result   Reference range
  ------------------------------------ ------------- --------------------
  Fibrinogen, mg/dL                    469           193-423
  Hematocrit, %                        41.6          34.0-44.0 (female)
  Hemoglobin, g/dL                     13.6          11.5-15.0 (female)
  International normalized ratio\*     \>12.0        2.0-3.5
  Partial thromboplastin time, s       \>120.0       25.0-35.0
  Platelet count,/µL                   285           150-450
  Prothrombin time, s                  \>130.0       9.1-12.0
  Quantitative D-dimer                 0.35          ...
  White blood cell count,/µL           12.1          3.9-11.0
  Serum Warfarin (HPLC assay), µg/mL   15.2          1.0-10.0
  Lactate dehydrogenase                330           \<215
  Fibrin Degradation Products, µg/mL   \<10          Negative: \<10

She returned 3 days later with similar complaints. We now suspected an intentional ingestion of warfarin given her occupation. An inpatient psychiatric consult revealed she might have come in contact with warfarin. Her sister takes warfarin for atrial fibrillation. The patient denied acute family-related or work-related stressors. Her previous admission factor results: Inhibitor screens were negative and specific coagulation factor assays were decreased for factor II, factor VII, factor IX and factor X as expected \[[Table 2](#T2){ref-type="table"}\]. Her initial Coumadin level was 15.2 ug/dL. Her PT and PTT were prolonged during the second admission as highlighted in [Table 3](#T3){ref-type="table"}. Her INR at second admission was \>12.0. She received IV Vitamin K 10 mg once and INR normalized. She was discharged on a tapering dose of Vitamin K.

###### 

Diagnostic lab results

  Mixing studies, s   Test result   Reference range
  ------------------- ------------- -----------------
  PTT (1:2 NP) mix    29.3          25.0-35.0
  PT (1:2 NP)         12            9.4-12.0
  Factor II, %        24            50-154
  Factor V, %         104           70-150
  Factor VII, %       37            51-186
  Factor IX, %        40            60-177
  Factor X, %         21            76-183

###### 

Repeat admission laboratory data

  Factor Tested                        Test result   Reference range
  ------------------------------------ ------------- --------------------
  Prothrombin time, s                  \>100.0       9.1-12.0
  Partial thromboplastin time, s       72            25.0-35.0
  International normalized ratio\*     \>12.0        2.0-3.5
  Fibrinogen, mg/dL                    482           193-423
  Fibrin Degradation Products, μg/mL   10            Negative:\<10
  Serum Warfarin (HPLC assay), μg/mL   12.1          1.0-10.0
  Hemoglobin, g/dL                     12.2          11.5-15.0 (female)
  Hematocrit, %                        37.5          34.0-44.0 (female)
  Platelet count,/μL                   367           150-450

Discussion {#sec1-3}
==========

The management of patients with an acute warfarin overdose is limited to case reports. Vitamin K antagonists are available ubiquitously and bleeding complications lasts for days to months after a single ingestion.\[[@ref5]\] Our patient had acute ecchymoses swiftly after her ingestion of warfarin. The toxicokinetics of warfarin suggest it can take 12 hours for the PT/INR to rise substantially.\[[@ref6]\] Her initial PT, PTT and INR were elevated suggesting she ingested the drug 12 hours prior to presentation. For her INR to rise significantly, her Factor VII levels should be 30% of baseline and they were 37% and the half-life of Factor VII is 6 hours. Our patient also denied taking fish oil and aspirin as they can disrupt platelet aggregation and can lead to bruising.

The management of warfarin overdose depends on the level of INR elevation and the urgency. Vitamin K is our initial drug of choice for treatment and FFP (fresh frozen plasma) is an option to be considered.\[[@ref2][@ref6]\] In accidental ingestion, high-dose oral therapy is preferable because there is no need to establish a therapeutic INR.\[[@ref1]\] The management of rodenticide overdose is different from warfarin overdose as the dose of vitamin K needed for rescue blockade of VKOR varies by patient.\[[@ref1]\] Superwarfarins have a longer half-life, hence studies highlight the role of prolonged vitamin K taper that can extend from 3 to 6 months to a year to help restore normal PT and coagulation factor levels.\[[@ref1][@ref7]\]

Munchausen syndrome is a psychiatric disorder in which sufferers intentionally fabricate physical or psychological symptoms to assume the role of the patient, without obvious gain.\[[@ref8]\] It has a preponderance for females employed in healthcare fields.\[[@ref4][@ref8]\] Most commonly these patients have personality disorders and depression.\[[@ref8]\] These individuals respond to stressful life events by using pathological behavior as a coping mechanism.\[[@ref8]\] The primary treatment is psychotherapy and cognitive behavioral therapy.\[[@ref8]\] When treatment is sought, the goal is to modify the person\'s behavior and reduce psychopathological burden of the condition.\[[@ref8]\]

It is important for PCPs to think of psychiatric causes of coagulopathies -- which can avoid confounding diagnoses and invasive investigations. Prompt primary care follow-up is needed since tapering doses of vitamin K need close observation. A multimodal approach with PCPs and psychiatrists is essential to long-term treatment of these patients.

Conclusion {#sec1-4}
==========

Our case uniquely highlights warfarin overdose in a patient with Munchausen syndrome. PCPs in particular must have a high suspicion to prevent inadequate treatment that exposes the patient to serious bleeding risk and potentially death.
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